Lifecore Biomedical, Inc.
LFCR- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001005286
No open-market purchases or sales by Lifecore Biomedical, Inc. insiders were filed in the last 90 days; 98 institutions reported holding it in 13F filings for Q2 2026, worth $133.3M in total; no superinvestor holds it.
13F holders, Q1 2026
Institutional positions in Lifecore Biomedical, Inc. as of Mar 31, 2026. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 105
- +2 vs. Q4 2025
- Shares held
- 25.1M
- +2.00M (+8.6%) vs. Q4 2025
- Total value
- $93.4M
- −$95.7M (−50.6%) vs. Q4 2025
- New holders
- 20
- 30 more added
- Sold out
- 18
- 33 more reduced
1 institution that held it in Q4 2025 haven't filed for Q1 2026 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q4 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting LFCR on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 98 | $133.3M |
| Q1 2026 | 105 | $93.4M |
| Q4 2025 | 104 | $202.8M |
| Q3 2025 | 100 | $179.1M |
| Q2 2025 | 87 | $198.0M |
| Q1 2025 | 87 | $190.0M |
| Q4 2024 | 76 | $202.4M |
| Q3 2024 | 82 | $117.0M |
| Q2 2024 | 75 | $119.4M |
| Q1 2024 | 79 | $114.4M |
| Q4 2023 | 78 | $131.3M |
| Q3 2023 | 69 | $132.5M |
| Q2 2023 | 75 | $173.9M |
| Q1 2023 | 82 | $81.7M |
| Q4 2022 | 93 | $160.0M |
| Q3 2022 | 86 | $220.0M |
| Q2 2022 | 90 | $252.1M |
| Q1 2022 | 97 | $278.9M |
| Q4 2021 | 98 | $287.2M |
| Q3 2021 | 92 | $235.5M |
| Q2 2021 | 95 | $285.5M |
| Q1 2021 | 93 | $275.2M |
Institutions, Q1 2026
Shares, value and share of portfolio for each institution holding Lifecore Biomedical, Inc.; share changes are against Q4 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| 325 Capital LLC | 2,162,466 | $8.04M | 2.93% | 00.0% | Unchanged |
| Greenhaven Road Investment Management, L.P. | 3,537,573 | $13.2M | 9.05% | −145,000−3.9% | Reduced |
| Legion Partners Asset Management, LLC | 4,461,823 | $16.6M | 12.05% | 00.0% | Unchanged |
| Wynnefield Capital Inc | 4,703,216 | $17.5M | 11.86% | 00.0% | Unchanged |
| 22NW, LP | 1,254 | – | – | 00.0% | Unchanged |
| Jane Street Group, LLC | 0 | $0 | 0.00% | −119,445−100.0% | Sold out |
| Pale Fire Capital SE | 0 | $0 | 0.00% | −71,040−100.0% | Sold out |
| D. E. Shaw & Co., Inc. | 0 | $0 | 0.00% | −37,428−100.0% | Sold out |
| Two Sigma Investments, LP | 0 | $0 | 0.00% | −27,803−100.0% | Sold out |
| PharVision Advisers, LLC | 0 | $0 | 0.00% | −19,041−100.0% | Sold out |
| Citadel Advisors LLC | 0 | $0 | 0.00% | −18,116−100.0% | Sold out |
| Two Sigma Advisers, LP | 0 | $0 | 0.00% | −15,264−100.0% | Sold out |
| Jump Financial, LLC | 0 | $0 | 0.00% | −15,061−100.0% | Sold out |
| Graham Capital Management, L.P. | 0 | $0 | 0.00% | −13,580−100.0% | Sold out |
| Intech Investment Management LLC | 0 | $0 | 0.00% | −11,724−100.0% | Sold out |
| MetLife Investment Management | 0 | $0 | 0.00% | −10,660−100.0% | Sold out |
| Torren Management, LLC | 0 | $0 | 0.00% | −2,312−100.0% | Sold out |
| Arbor Wealth Management LLC | 0 | $0 | 0.00% | −1,674−100.0% | Sold out |
| Quarry LP | 0 | $0 | 0.00% | −1,400−100.0% | Sold out |
| Kemnay Advisory Services Inc. | 0 | $0 | 0.00% | −975−100.0% | Sold out |
| Amalgamated Bank | 0 | $0 | 0.00% | −877−100.0% | Sold out |
| Jones Financial Companies LLLP | 0 | $0 | 0.00% | −23−100.0% | Sold out |
| SRS Capital Advisors, Inc. | 0 | $0 | 0.00% | −5−100.0% | Sold out |
| Vanguard Group Inc | – | – | – | – | Not filed |